Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
复制标题
斯威特综合征——急性发热性中性粒细胞性皮肤病的综合综述。
DOI：
10.1186/1750-1172-2-34
复制
发表时间：
2007-07-26
影响因子：
3.7
通讯作者：
Cohen PR
中科院分区：
文献类型：
--
作者：
Cohen PR
Sweet综合征（急性发热性嗜中性粒细胞皮肤病的代名词）的特征在于一系列临床症状、身体特征和病理学发现，包括发热、嗜中性粒细胞、压痛性皮肤病变（丘疹、结节和斑块）和主要由通常位于真皮上层的成熟中性粒细胞组成的弥漫性浸润。已经发表了数百例Sweet综合征病例。Sweet综合征有三种临床表现：经典型（或特发性）、恶性肿瘤相关型和药物诱导型。经典Sweet综合征（CSS）通常出现在30至50岁的女性中，通常在上呼吸道感染之前，可能与炎症性肠病和妊娠有关。大约三分之一的CSS患者会出现皮肤病复发。恶性肿瘤相关的Sweet综合征（MASS）可以作为一种副肿瘤综合征发生在已确诊的癌症患者或以前未发现Sweet综合征相关的血液恶液质或实体瘤的个体中; MASS最常与急性髓细胞性白血病相关。皮肤病可以在患者癌症诊断之前、之后或同时出现。因此，MASS可以是先前无癌症个体中未诊断的内脏恶性肿瘤或肿瘤患者中未怀疑的癌症复发的皮肤先兆。药物诱导的Sweet综合征（DISS）最常发生在接受粒细胞集落刺激因子治疗的患者中，然而，其他药物也可能与DISS相关。Sweet综合征的发病机制可能是多因素的，仍然有待明确确定。临床和实验室证据表明，细胞因子具有病因学作用。全身性皮质类固醇是Sweet综合征的治疗金标准。在开始用全身性皮质类固醇治疗后，有迅速的反应，包括皮肤病相关症状和皮肤病变的显著改善。局部应用高效皮质类固醇或病灶内皮质类固醇可有效治疗局部病变。其他一线口服全身性药物是碘化钾和秋水仙碱。二线口服全身性药物包括吲哚美辛、氯法齐明、环孢素和氨苯砜。Sweet综合征的症状和病变可以自发消退，无需任何治疗干预;然而，复发可能发生在自发缓解或治疗诱导的临床消退之后。
Sweet's syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis. Several hundreds cases of Sweet's syndrome have been published. Sweet's syndrome presents in three clinical settings: classical (or idiopathic), malignancy-associated, and drug-induced. Classical Sweet's syndrome (CSS) usually presents in women between the age of 30 to 50 years, it is often preceded by an upper respiratory tract infection and may be associated with inflammatory bowel disease and pregnancy. Approximately one-third of patients with CSS experience recurrence of the dermatosis. The malignancy-associated Sweet's syndrome (MASS) can occur as a paraneoplastic syndrome in patients with an established cancer or individuals whose Sweet's syndrome-related hematologic dyscrasia or solid tumor was previously undiscovered; MASS is most commonly related to acute myelogenous leukemia. The dermatosis can precede, follow, or appear concurrent with the diagnosis of the patient's cancer. Hence, MASS can be the cutaneous harbinger of either an undiagnosed visceral malignancy in a previously cancer-free individual or an unsuspected cancer recurrence in an oncology patient. Drug-induced Sweet's syndrome (DISS) most commonly occurs in patients who have been treated with granulocyte-colony stimulating factor, however, other medications may also be associated with DISS. The pathogenesis of Sweet's syndrome may be multifactorial and still remains to be definitively established. Clinical and laboratory evidence suggests that cytokines have an etiologic role. Systemic corticosteroids are the therapeutic gold standard for Sweet's syndrome. After initiation of treatment with systemic corticosteroids, there is a prompt response consisting of dramatic improvement of both the dermatosis-related symptoms and skin lesions. Topical application of high potency corticosteroids or intralesional corticosteroids may be efficacious for treating localized lesions. Other first-line oral systemic agents are potassium iodide and colchicine. Second-line oral systemic agents include indomethacin, clofazimine, cyclosporine, and dapsone. The symptoms and lesions of Sweet's syndrome may resolved spontaneously, without any therapeutic intervention; however, recurrence may follow either spontaneous remission or therapy-induced clinical resolution.
登录
查看更多内容
影响因子：
--
作者：
Ayirookuzhi, SJ;Ramshesh, P;Mills, G
通讯作者：
Mills, G
影响因子：
--
作者：
ARAM, H
通讯作者：
ARAM, H
DOI：
10.1016/0190-9622(95)91382-3
发表时间：
1995-09-01
影响因子：
13.8
作者：
ASNIS, LA;GASPARI, AA
通讯作者：
GASPARI, AA
影响因子：
0.9
作者：
Abecassis, S;Ingen-Housz-Oro, S;Dubertret, L
通讯作者：
Dubertret, L
影响因子：
17.3
作者：
ANSTEY, A;WILKINSON, JD;GOWERS, L
通讯作者：
GOWERS, L